menu search

GANX / Why Is Gain Therapeutics (GANX) Stock Moving Today?

Why Is Gain Therapeutics (GANX) Stock Moving Today?
Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a press release from Gain Therapeutics, the company has started dosing the first two subjects in its Phase 1 clinical trial. Read More
Posted: Oct 4 2023, 08:45
Author Name: InvestorPlace
Views: 112585

GANX News  

Why Is Gain Therapeutics (GANX) Stock Moving Today?

By InvestorPlace
October 4, 2023

Why Is Gain Therapeutics (GANX) Stock Moving Today?

Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a p more_horizontal

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

By GlobeNewsWire
September 25, 2023

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the disc more_horizontal

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 10, 2023

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares more_horizontal

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 12, 2023

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares more_horizontal

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

By GlobeNewsWire
March 29, 2023

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease more_horizontal

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 16, 2022

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numb more_horizontal

Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

By Benzinga
March 15, 2022

Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs.  These results were more_horizontal


Search within

Pages Search Results: